Intravacc and Primrose Bio Renew Partnership for Conjugate Vaccine Development
Intravacc and Primrose Bio have renewed their strategic partnership to enhance conjugate vaccine development and supply. The collaboration offers a comprehensive solution for companies developing conjugate vaccines.
Intravacc, a Contract Development and Manufacturing Organization (CDMO) specializing in vaccines and biologics for infectious diseases, and biotechnology company Primrose Bio have renewed their strategic partnership to enhance the development and supply of conjugate vaccines.
The renewed collaboration will leverage the combined expertise of both companies to offer a seamless solution for third parties involved in the development, manufacturing, and supply of conjugate vaccines. Intravacc brings its know-how in antigen conjugation process development, scale-up, and GMP production, while Primrose Bio supplies its industry-leading PeliCRM197® carrier protein and provides supply chain and regulatory support.
"We are excited to renew our partnership with Primrose Bio," said Ivo Lemmens, Intravacc's managing director. "By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide."
Andrew Burch, Primrose Bio’s CEO, added: "Expanding the capability of our PeliCRM197® franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole."
The partnership aims to advance vaccine development and improve accessibility for researchers and industry clients. Intravacc and Primrose Bio have previously collaborated under this partnership.